Crossref
PROCEADE\xAE‐CRC‐03: A Phase 3 study of precemtabart tocentecan (Precem‐TcT), as monotherapy or plus bevacizumab, in patients with advanced metastatic colorectal cancer (mCRC)
Asia-Pacific Journal of Clinical Oncology · 2026-11 · 22 (S6) · 19-19
DOI: 10.1111/ajco.70234 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, online erschienen am 19.11.2026.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). PROCEADE\xAE‐CRC‐03: A Phase 3 study of precemtabart tocentecan (Precem‐TcT), as monotherapy or plus bevacizumab, in patients with advanced metastatic colorectal cancer (mCRC). Asia-Pacific Journal of Clinical Oncology, 22(S6), 19-19. https://doi.org/10.1111/ajco.70234
Vancouver
PROCEADE\xAE‐CRC‐03: A Phase 3 study of precemtabart tocentecan (Precem‐TcT), as monotherapy or plus bevacizumab, in patients with advanced metastatic colorectal cancer (mCRC). Asia-Pacific Journal of Clinical Oncology. 2026;22(S6):19-19. doi:10.1111/ajco.70234
BibTeX
@article{euvimed2026,
title = {PROCEADE\xAE‐CRC‐03: A Phase 3 study of precemtabart tocentecan (Precem‐TcT), as monotherapy or plus bevacizumab, in patients with advanced metastatic colorectal cancer (mCRC)},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
volume = {22},
number = {S6},
pages = {19--19},
doi = {10.1111/ajco.70234}
}
EUVIMED